Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 0.6325 CHF -50.35% Market Closed
Market Cap: 114m CHF
Have any thoughts about
Idorsia Ltd?
Write Note
IDIA
/
Balance Sheet
/
Total Receivables

Idorsia Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Idorsia Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Idorsia Ltd
SIX:IDIA
Total Receivables
CHf29.9m
CAGR 3-Years
41%
CAGR 5-Years
70%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Total Receivables
CHf26.2m
CAGR 3-Years
303%
CAGR 5-Years
46%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Total Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Total Receivables
CHf3.4m
CAGR 3-Years
-25%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Total Receivables
CHf48.9m
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
15%
Kuros Biosciences AG
SIX:KURN
Total Receivables
CHf11m
CAGR 3-Years
71%
CAGR 5-Years
68%
CAGR 10-Years
N/A
No Stocks Found

Idorsia Ltd
Glance View

Market Cap
119.1m CHF
Industry
Biotechnology

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

IDIA Intrinsic Value
Not Available
What is Intrinsic Value?

See Also

What is Idorsia Ltd's Total Receivables?
Total Receivables
29.9m CHF

Based on the financial report for Dec 31, 2023, Idorsia Ltd's Total Receivables amounts to 29.9m CHF.

What is Idorsia Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
70%

Over the last year, the Total Receivables growth was -39%. The average annual Total Receivables growth rates for Idorsia Ltd have been 41% over the past three years , 70% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.